NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Home
Companies
NanoViricides, Inc.

BRIEF

published on 10/15/2024 at 12:35, 1 month 6 days ago

Une technologie antivirale innovante évoquée dans le récent podcast NanoViricides

NanoViricides NV-387 Traitement Antiviral Essais De Phase II Technologie De La Nanomédecine
PRESS RELEASE

published on 10/15/2024 at 12:30, 1 month 6 days ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
NanoViricides, Inc. announces interview with Dr. Diwan discussing revolutionary broad-spectrum antiviral clinical drug candidate NV-387 and innovative nanoviricide technology platform

NV-387 Clinical Trials NanoViricides Inc. Antiviral NanoViricides Technology
BRIEF

published on 10/08/2024 at 12:35, 1 month 13 days ago

NanoViricides to Address AMR Summit 2024 on Innovative Drug Technologies

Antimicrobial Resistance Clinical Trials AMR Summit 2024 NanoViricides Technology NV-387 Drug
BRIEF

published on 10/08/2024 at 12:35, 1 month 13 days ago

NanoViricides participera au Sommet AMR 2024 sur les technologies pharmaceutiques innovantes

Essais Cliniques Résistance Aux Antimicrobiens Sommet AMR 2024 Technologie Des Nanoviricides Médicament NV-387
PRESS RELEASE

published on 10/08/2024 at 12:30, 1 month 13 days ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Dr. Diwan to discuss NanoViricides' pathogen-directed attack technology combating AMR at the Global AMR Summit, highlighting the 'shape-shifting' nanoviricide platform

NanoViricides Antiviral AMR Nanomedicines Pathogen-directed Therapy
BRIEF

published on 09/30/2024 at 12:35, 1 month 21 days ago

NanoViricides Reports Annual Financials and Advances NV-387 to Phase II Trials

NanoViricides NV-387 Financial Report Antiviral Drug Phase II Trials
BRIEF

published on 09/30/2024 at 12:35, 1 month 21 days ago

NanoViricides publie ses résultats financiers annuels et fait progresser le NV-387 vers les essais de phase II

NanoViricides NV-387 Rapport Financier Médicament Antiviral Essais De Phase II
PRESS RELEASE

published on 09/30/2024 at 12:30, 1 month 21 days ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
NanoViricides, Inc. reports filing of Annual Report on Form 10-K for fiscal year 2024, financial updates, and plans for Phase II clinical trials of antiviral drug NV-387

NanoViricides NV-387 Financial Updates Form 10-K Phase II Clinical Trials
BRIEF

published on 09/26/2024 at 12:35, 1 month 25 days ago

NanoViricides Signs Comprehensive Antiviral Drug Agreement With TheraCour Pharma

NanoViricides NV-387 Antiviral Drugs TheraCour Pharma Trojan Horse Drugs
BRIEF

published on 09/26/2024 at 12:35, 1 month 25 days ago

NanoViricides signe un accord global sur les médicaments antiviraux avec TheraCour Pharma

NanoViricides NV-387 Médicaments Antiviraux TheraCour Pharma Drogues Du Type Cheval De Troie

Accesswire

Published on 11/21/2024 at 12:00, 57 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 57 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 27 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 54 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 57 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 22 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 42 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 51 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 57 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 27 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 5 hours 59 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 59 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 59 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 50 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 37 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE